STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer.

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) patients have a significantly higher risk of developing colorectal cancer (CRC).
• Colorectal cancer in IBD patients is often diagnosed at a later stage and has a poorer prognosis.
• Targeting STAT3 signaling is a potential therapeutic strategy for IBD-associated CRC.

Purpose of the Study:

• To evaluate the efficacy of TTI-101, a small-molecule STAT3 inhibitor, in a mouse model of colitis-associated colorectal cancer.
• To determine if targeting STAT3 with TTI-101 can reduce tumor development and modulate relevant molecular pathways.

Main Methods:

• The azoxymethane (AOM)-disodium sulfate (DSS) mouse model was used to induce colitis-associated CRC.
• Mice were treated with TTI-101 (50 mg/kg) or vehicle via oral gavage for 28 days.
• Adenoma numbers, levels of activated STAT3 (pY-STAT3), and colon transcriptome were analyzed.

Main Results:

• TTI-101 treatment reduced adenoma numbers by 89% compared to vehicle control (p ≤ 0.05).
• Activated STAT3 levels were elevated in dysplastic mucosa and correlated with adenoma number.
• TTI-101 was detected in plasma and colon tissue, with levels inversely correlating to pY-STAT3.
• TTI-101 normalized the colon transcriptome and reduced expression of oncogenic STAT3/STAT1-upregulated genes.

Conclusions:

• TTI-101 effectively suppresses tumor development in a colitis-associated CRC mouse model.
• STAT3 signaling is a key driver in IBD-associated CRC oncogenesis.
• TTI-101 demonstrates potential as a therapeutic agent for IBD patients with CRC.